3 4 6 6 5

论文已发表


注册即可获取德孚的最新动态



IF 收录期刊





更多详情 >>



会员计划

我们很高兴为机构提供一种切实的方法以支持开放获取并鼓励教师和研究人员通过开放获取模式尽可能广泛地传播他们的作品。

更多详情 >>

 

加入德孚官方微信,即可享受论文费用7.5折

视频

Human mesenchymal stem cell-derived iron oxide exosomes allow targeted ablation of tumor cells via magnetic hyperthermia

 

Authors Altanerova U, Babincova M, Babinec P, Benejova K, Jakubechova J, Altanerova V, Zduriencikova M, Repiska V, Altaner C

Received 28 June 2017

Accepted for publication 9 September 2017

Published 27 October 2017 Volume 2017:12 Pages 7923—7936

DOI https://doi.org/10.2147/IJN.S145096

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Govarthanan Muthusamy

Peer reviewer comments 3

Editor who approved publication: Dr Thomas J Webster

Abstract: Magnetic hyperthermia, or the heating of tissues using magnetic materials, is a promising approach for treating cancer. We found that human mesenchymal stem cells (MSCs) isolated from various tissues and MSCs expressing the yeast cytosine deaminase::uracil phosphoribosyl transferase suicide fusion gene (y CD::UPRT ) can be labeled with Venofer, an iron oxide carbohydrate nanoparticle. Venofer labeling did not affect cell proliferation or the ability to home to tumors. All Venofer-labeled MSCs released exosomes that contained iron oxide. Furthermore, these exosomes were efficiently endocytosed by tumor cells. Exosomes from Venofer-labeled MSCs expressing the y CD::UPRT  gene in the presence of the prodrug 5-fluorocytosine inhibited tumor growth in a dose-dependent fashion. The treated tumor cells were also effectively ablated following induction of hyperthermia using an external alternating magnetic field. Cumulatively, we found that magnetic nanoparticles packaged into MSC exosomes are efficiently endocytosed by tumor cells, facilitating targeted tumor cell ablation via magnetically induced hyperthermia.
Keywords: mesenchymal stem cells, iron oxide labeling, Venofer, yCD::UPRT -exosomes, yCD::UPRT -MSCs/Fe exosomes, magnetic hyperthermia


 

摘要视频链接MSCiron oxide exosomes for cancer therapy